RNVS - Renovis! Aktie notiert nun unter Buchwert. - 500 Beiträge pro Seite

[GerdKill]

Die Aktie ist im Oktober ordentlich verprügelt worden.
Die derzeitige Bewertung erscheint mir allerdings etwas sehr konservativ -
oder übersehe ich da wichtige Faktoren??




Gruss
Gerd

[GerdKill]

Antwort auf Beitrag Nr.: 26.630.145 von GerdKill am 01.01.07 19:13:42

und diese Meldung war der Auslöser für den drawdown:



AstraZeneca stops development of stroke drug
Another high-profile setback for Anglo-Swedish pharmaceutical
PrintE-mailDisable live quotesRSSDigg itDel.icio.usBy Steve Goldstein, MarketWatch
Last Update: 11:00 AM ET Oct 26, 2006


LONDON (MarketWatch) -- AstraZeneca on Thursday said it was stopping development of a stroke drug in yet another blow to the Anglo-Swedish pharmaceutical, and one that proved devastating to shares of its partner, Renovis.
AstraZeneca (AZN : astrazeneca plc sponsored adr
News , chart, profile, more
Last: 53.55-0.25-0.46%

4:00pm 12/29/2006

Delayed quote dataAdd to portfolio
Analyst
Create alertInsider
Discuss
Financials
Sponsored by:
AZN53.55, -0.25, -0.5%) (UK:AZN: news, chart, profile) said it would stop development of NXY-059, following a results from a Phase III trial that showed it didn't meet its primary outcome of a statistically significant reduction in stroke-related disability, when compared to placebo.
The drug also didn't cause a statistically significant boost to neurological status and no evidence of lowering the incidence of symptomatic intracranial haemorrhage.
"These clinical trial results, while not without precedent given the challenging nature of the science, are disappointing for patients looking for new treatments for stroke and for AstraZeneca as we seek to build our research and development pipeline," said John Patterson, executive director of development.
Renovis (RNVS : renovis inc com
News , chart, profile, more
Last: 3.16+0.11+3.61%

4:01pm 12/29/2006

Delayed quote dataAdd to portfolio
Analyst
Create alertInsider
Discuss
Financials
Sponsored by:

RNVS3.16, +0.11, +3.6%) , its partner on the drug, said it's in a strong financial position to continue drug discovery programs on its own and will continue to partner with Pfizer (PFE : Pfizer Inc
News , chart, profile, more
Last: 25.90-0.17-0.65%

4:01pm 12/29/2006

Delayed quote dataAdd to portfolio
Analyst
Create alertInsider
Discuss
Financials
Sponsored by:
PFE25.90, -0.17, -0.7%) and Genentech (DNA : genentech inc com new
News , chart, profile, more
Last: 81.13+0.02+0.02%

4:01pm 12/29/2006

Delayed quote dataAdd to portfolio
Analyst
Create alertInsider
Discuss
Financials
Sponsored by:

DNA81.13, +0.02, +0.0%) .
Renovis shares dropped 73% in New York on the news.
For AstraZeneca, the setback is the latest after failures with drugs including blood thinner Exanta, lung cancer drug Iressa and diabetes drug Galida.
Analysts at Goldman Sachs had called NXY-059 a "high-risk" project -- it didn't assume any revenue from the product in its earnings model -- but noted that if the drug reached blockbuster status, or sales of over $1 billion, in its fifth year it would be worth 1.30 pounds a share.
London-listed AstraZeneca shares dropped 8.3%, or 2.92 pounds, at 32.36 pounds a share.
The company also reported third-quarter profit that exceeded analyst expectations. See AstraZeneca earnings story.
Steve Goldstein is MarketWatch's London bureau chief.


Related Blog Posts & Articles

[GerdKill]

Date Insider Shares Transaction Value

12/15/06 WALKER, JOHN PETER,
Director 40,000 Sell at $3.08 per share. $123,204 2/27/06 WALKER, JOHN PETER,
Director 20,000 Sell at $21.65 - $21.80 per share. $434,500
5/12/05 WALKER, JOHN PETER,
Director 10,000 Sell at $18.00 per share. $180,000
12/10/04 WALKER, JOHN PETER,
Director 44,954 Sell at $13.50 - $14.02 per share. $618,567

das gibt allerdings Rätsel auf...

[GerdKill]

September 2006
Short
Interest Percent
Change Average Daily
Share Volume Days to
Cover
RNVS Renovis, Inc. - Common Stock 5,420,011 8.56 198,018 27.37


October 2006
Short
Interest Percent
Change Average Daily
Share Volume Days to
Cover
RNVS Renovis, Inc. - Common Stock 5,613,822 3.58 393,694 14.26


November 2006
Short
Interest Percent
Change Average Daily
Share Volume Days to
Cover
RNVS Renovis, Inc. - Common Stock 5,854,285 4.28 3,914,490 1.50


December 2006
Short
Interest Percent
Change Average Daily
Share Volume Days to
Cover
RNVS Renovis, Inc. - Common Stock 3,998,677 (31.70) 703,170 5.69

die shorties sind teilweise schon flat -
und trotzdem fiel der Kurs weiter..

[GerdKill]

was ist faul hier?
---------------------

Insider
Select an insider below for more information. Relation Last
Date Form
Type Trans
Type Own
Type Shares
Traded Last
Price Shares
Held
GOODMAN COREY S OFF 12/18/2006 Form 4 AS IN (1,852) $3.091 191,956

WALKER JOHN PETER DIR 12/15/2006 Form 4 S IN (40,000) $3.080 60,840

GOODMAN COREY S OFF 11/20/2006 Form 4 AS IN (1,852) $3.381 193,808

DOYLE JOHN C OFF 11/02/2006 Form 4 S D (50,000) $3.236 28,936

GOODMAN COREY S OFF 10/27/2006 Form 4 AS IN (20,649) $3.520 195,660

GOODMAN COREY S OFF 10/26/2006 Form 4 AS IN (25,000) $3.741 216,309

GOODMAN COREY S OFF 10/02/2006 Form 4 AS IN (6,000) $13.500 246,801

GOODMAN COREY S OFF 09/01/2006 Form 4 AS IN (6,000) $14.470 253,009

GOODMAN COREY S OFF 08/01/2006 Form 4 AS IN (6,000) $12.110 258,709

GOODMAN COREY S OFF 07/03/2006 Form 4 AS IN (6,000) $15.240 264,909

GOODMAN COREY S OFF 06/01/2006 Form 4 AS IN (6,000) $16.140 271,210

DOYLE JOHN C OFF 05/25/2006 Form 4 Option OE D 10,300 $1.125 78,715

[BrauchGeld]

Antwort auf Beitrag Nr.: 26.630.287 von GerdKill am 01.01.07 20:03:03

Ein tolles upgrade das ich mit Matrix Research teile

http://finance.yahoo.com/q/ud?s=RNVS

Date Research Firm Action From To
30-Oct-06 Matrix Research Upgrade Strong Sell Sell

[GerdKill]

Antwort auf Beitrag Nr.: 26.630.559 von BrauchGeld am 01.01.07 22:00:28

aha -
und warum bist Du dieser Ansicht??

[GerdKill]

heute zu 3,18 mit erster Posi rein


aktuell 3,33$
so kann es gerne weiter gehen...

[GerdKill]

mal abwarten, ob wir die 3,60 überwinden können.
Umsätze sind recht hoch.

[zenman]

da is jetz en GAP



die insiderverkäufe machen mich misstrauisch :O

der UP könnte ausschliesslich charttechn. natur sein
ist einfach fällig jetzt
die frage ist
gehts weiter up
oder
erstmal korrektur

ich wart mal ab

zen

[zenman]

na
dann mach ich mal weiter

January 23, 2007 - 5:00 PM EST

close Email this News Article
Your Name
Your Email
Friend's Name
Friend's Email
Receive Copy: yes

RNVS 3.45 0.06
Today 5d 1m 3m 1y 5y 10y



Renovis Restructures to Focus on Advancing Its Neurological and Inflammatory Disease Programs Into Clinical Trials
SOUTH SAN FRANCISCO, Calif., Jan. 23 /PRNewswire-FirstCall/ -- Renovis, Inc. (Nasdaq: RNVS) today announced that it has reduced its workforce by approximately 40 percent of its positions as part of a restructuring plan intended to significantly reduce spending while maintaining the research and development capabilities needed to advance the Company's late-stage preclinical drug discovery programs. The Company's VR1 collaboration with Pfizer and its ability to advance its unpartnered programs focused on antagonists of the purinergic receptors P2X7 and P2X3 are unaffected by the restructuring.

'Each of our proprietary programs has the potential to yield breakthrough treatments for major medical needs in neurological or inflammatory disease indications and this action properly staffs us to advance these late-stage preclinical programs into the clinic with existing financial resources,' said Corey S. Goodman, Ph.D., President and Chief Executive Officer. 'The VR1 program with Pfizer is on track to enter clinical development this year and we are targeting 2008 to advance our P2X7 and P2X3 programs into clinical studies for inflammatory disease and pain indications, as appropriate. We are deeply grateful for the contributions and hard work of the talented and dedicated employees who will be leaving Renovis and wish them great success in their future endeavors.'

'We recently selected a clinical candidate from our P2X7 program with the intention of initiating IND enabling studies in the first half of this year,' said Michael G. Kelly, Ph.D., Senior Vice President, Research and Development. 'It is particularly difficult to part ways with highly capable employees who have made important contributions to this achievement as well as our progress on the VR1 and P2X3 programs. However, after this action we are well positioned to accomplish our goals and the team is committed to doing so.'

The Company is providing severance and career transition assistance to the employees directly affected by the restructuring, and Renovis expects to incur restructuring charges of approximately $1.0 million in the first quarter of 2007, primarily associated with severance benefits. The Company expects to have approximately 70 employees following the workforce reduction. As of September 30, 2006, Renovis had cash, cash-equivalents, and marketable securities of $104.7 million. Based on current projections, the Company expects current cash, cash equivalents, and marketable securities to be sufficient to fund projected activities at least through the end of 2009.

Renovis will provide financial guidance for 2007 and review the progress of its programs in its fourth quarter and year-end 2006 financial results announcement scheduled for March 1, 2007.

[zenman]

Renovis Tries to Right Itself
By Brian Lawler
January 25, 2007
It's just a fact of the industry that, inevitably, every year several development-stage biotechs implode after their lead compounds fail to pass muster in clinical trials. Unfortunately for shareholders in drug developer Renovis (Nasdaq: RNVS), it became one of those biotechs last year, after its lead drug failed in a pivotal phase 3 clinical trial.

If you recall, Renovis and partner AstraZeneca (NYSE: AZN) reported phase 3 results from their SAINT II clinical trial back in October for candidate NXY-059. The drug failed to show a statistically significant reduction (p-value of 0.33) in stroke-related disability compared to placebo, and it also missed its secondary endpoints. Considering the more than 3,000 patients in the trial, it's probably fair to say that these results were most likely not due to the trial being underpowered.

Investors had high hopes for NXY-059 after an earlier 1,700-person phase 3 trial, titled SAINT I, succeeded in the same primary endpoint (with a p-value of 0.038) but failed in its secondary endpoints. Either something went wrong with the second SAINT trial compared to this one, or else these first results may have been a statistical fluke. Remember, a p-value of 0.038 means there's nearly a 4% chance that the results could occur by chance. That's why the FDA almost always requires two successful phase 3 trials for a drug to gain marketing approval.

On Tuesday, Renovis partly outlined the steps it was taking in light of the failure of its stroke treatment NXY-059. It announced a 40% reduction in its workforce to conserve its $105 million in cash and equivalents, and also reiterated its commitment to the compounds in its pipeline. Really though, what other choice does Renovis have?

Barring an acquisition -- a possibility to which Renovis seemed open in its third-quarter financial release -- the company also guided for its cash stockpile to last it until "at least" the end of 2009. Considering that all the drug candidates in Renovis' pipeline are in the preclinical stage -- except for a partnered pain drug with Pfizer (NYSE: PFE) that is just entering phase 1 testing -- this rate of cash burn sounds reasonable.

It's way too soon for me to make any judgment on the value of Renovis' pipeline, since none of the compounds have any clinical trial results attached to them. By 2008, Renovis expects to have three drugs in phase 1 testing. If there is any meaningful value in these compounds then shares of Renovis might be a deal right now, just considering the breakup value of the company.

As of last year's third quarter, Renovis had net cash and equivalents of approximately $105 million. Even with a couple of million dollars in cash burn for the fourth quarter, it's now barely trading above its cash level. Considering the other opportunities out there in this sector, though, it's tough to generate any interest for a biotech whose products have so many unknowns attached to them.

[GerdKill]

Antwort auf Beitrag Nr.: 27.319.455 von zenman am 31.01.07 14:01:54

3,18 - 3,68

hab schon schlechtere Einstände gehabt.

[US336]

Pfizer and Renovis Extend Research Collaboration to Identify Small Molecule VR1 Antagonists



SOUTH SAN FRANCISCO, Calif., April 10 /PRNewswire-FirstCall/ --
Renovis, Inc. (Nasdaq: RNVS), a biopharmaceutical company focused on the
discovery and development of drugs for major medical needs in the areas of
neurological and inflammatory diseases, today announced an agreement with
Pfizer Inc. (NYSE: PFE) to extend the term of the companies' worldwide
collaboration to research, develop and commercialize small molecules that
target the vanilloid receptor, VR1. This extension provides Renovis with
additional research funding through June 30, 2008 and reflects the goal of
Pfizer and Renovis to advance multiple, small molecule VR1 antagonists
toward clinical development.
The VR1 receptor is a member of a related group of ion channel proteins
known as the transient receptor potential (TRP) family that mediate and
influence cell signaling. Inhibitors of VR1 are predicted to be useful in
the treatment of pain, urinary incontinence and other diseases and
disorders.
"We partnered our VR1 program with Pfizer in June 2005 at a preclinical
stage because we believed that safe and effective antagonists of VR1 could
potentially address major medical needs in multiple therapeutic areas and
we wanted to work with a partner capable of aggressively pursuing this
broad potential with us," stated Corey S. Goodman, Ph.D., President and
Chief Executive Officer of Renovis. "Since then, the collaboration has
produced its first advanced candidate, which we expect to enter human
testing in 2007, as well as several other small molecule VR1 antagonists
that we hope to advance into IND-enabling studies and clinical development
with Pfizer during the term of this extension."
"VR1 antagonists represent an enormous opportunity to help large
numbers of patients who are poorly served by existing therapies," added
Michael G. Kelly, Ph.D., Senior Vice President of Research and Development.
"We are strongly committed to doing all that we can with Pfizer to deliver
on this promise."
Under the terms of the extension, Pfizer will continue to fund all
aspects of the collaboration including the research and preclinical
development efforts at Renovis through June 30, 2008. Other terms of the
collaboration and licensing agreements between Pfizer and Renovis have not
been changed.
2007 Financial Guidance
Financial projections involve a high level of uncertainty due, among
many factors, to the variability involved in predicting requirements of
drug discovery and clinical development activities and the potential for
Renovis to enter into new licensing agreements or strategic collaborations.
We plan to update financial guidance for 2007, as necessary, when we
release results for each quarter or upon the announcement of material
corporate events.
For the year ending December 31, 2007, the Company has updated its
financial guidance as previously announced in conjunction with its results
for the year ended December 31, 2007, to give effect to the extension of
its collaboration with Pfizer. The Company now expects:
-- total contract revenue from existing agreements of $5.3 million to $9.8
million; and
-- total operating expenses of $28.0 million to $32.0 million, excluding
non-cash, stock-based compensation to be recognized in accordance with
SFAS No. 123R and $1.1 million in restructuring expense that we
recorded in the first quarter of 2007.
About Renovis
Renovis is a biopharmaceutical company focused on the discovery and
development of drugs for major medical needs in the areas of neurological
and inflammatory diseases. The Company's proprietary research programs
focus on purinergic receptors for the potential treatment of pain and
inflammatory diseases. In addition, Renovis has a worldwide collaboration
and license agreement with Pfizer to research, develop and commercialize
small molecule vanilloid receptor (VR1) antagonists, and a research and
development collaboration with Genentech to discover and develop
anti-angiogenesis drugs and drugs that promote nerve re-growth following
nervous system injury.
For additional information about the company, please visit
http://www.renovis.com.
Safe Harbor Statement
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 that
involve substantial risks and uncertainties. All statements, other than
statements of historical facts, included in this press release regarding
our strategy, future operations, future financial results, future revenues,
future operating expenses, future preclinical and clinical development,
plans and objectives of management are forward-looking statements. We may
not actually achieve these plans, intentions or expectations and Renovis
cautions investors not to place undue reliance on our forward-looking
statements. Actual results or events could differ materially from the
plans, intentions and expectations disclosed in the forward-looking
statements we make. Various important factors that could cause actual
results or events to differ materially from the forward- looking statements
that we make are described in greater detail in the reports we file with
Securities and Exchange Commission, including the "Risk Factors" section of
our Annual Report on Form 10-K, which was filed with the Securities and
Exchange Commission on March 15, 2007. Renovis is providing this
information as of the date of this press release and does not undertake any
obligation to update any forward-looking statements as a result of new
information, future events or otherwise.



SOURCE Renovis, Inc.

--------------------------------------------------------------------------------